Clinical trials: Breast Cancer (Early Breast Cancer)
Early-Stage Breast Carcinoma
TARGeted Intraoperative radioTherapy (TARGIT) Registry Database
This is a prospectively registered database of patients with early breast cancer who will be treated with radiotherapy during surgery. More than 2000 women have already received this treatment in clinical trials.
- Trial name
- TARGIT R (NCT02947425)
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University College, London
Fatigue
Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer
This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.
- Trial name
- NCT02521077
- Testing
- Ascorbic Acid, Normal Saline
- Sponsor
- Midwestern Regional Medical Center
Early Breast Cancer, Triple Negative Breast Cancer
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
Phase II, randomized, Active-controlled open label trial for treatment of high risk, HR-/HER2- (triple negative) breast cancer, with two sequences of neoadjuvant chemotherapy on a background of pembrolizumab
- Trial name
- KEYPARTNER (NCT06371807)
- Testing
- Pembrolizumab injection
- Where
- 3 sites in Portugal
- Volunteers
- 20 people
- Sponsor
- Fundacao Champalimaud
Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
Some cancer treatments, such as anthracycline chemotherapy and HER2-targeted therapy, can damage the heart (cardiotoxicity). If heart damage is detected early, heart-protective treatment can be started and cancer treatment can…
- Conditions
- Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer, Cardiotoxicity
- Trial name
- SAFE-HEART (NCT07916337)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Skane
TNBC - Triple-Negative Breast Cancer, TNBC
Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer
This is a single-arm and single site phase II trial combination of chemotherapy and pembrolizumab with LBP MO-03 in 50 trial participants with early triple negative breast cancer.
- Conditions
- TNBC - Triple-Negative Breast Cancer, TNBC, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07552181
- Testing
- Live biotherapeutic product: MO-03 1 capsule PO BID
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Yuan Yuan
Breast Cancer
Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
Stereotactic radiation has been implemented more than 3 decades ago, initially to radiate benign and later malignant tumors within the brain. Doses up to 24 Gy in one session have been used.
- Trial name
- NCT03581136
- Testing
- Dose Fractionation
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Texas Southwestern Medical Center
Early Triple Negative Breast Cancer
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy
The purpose of this study is to assess efficacy of platinum-based neoadjuvant chemotherapy in correlation with BRCA1-associated DNA repair dysfunction in patients with early triple negative breast cancer.
- Trial name
- NCT01672671
- Testing
- Doxorubicin, Paclitaxel, Cisplatin
- Where
- Russia
- Volunteers
- 41 people
- Sponsor
- Russian Academy of Medical Sciences
Early-Stage Breast Carcinoma
Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer
Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible. Investigators initiated this multicenter two-armed phase III prospective trial to analyse the…
- Trial name
- HYPOSIB (NCT02474641)
- Testing
- Standard Radiation, Hypofractionation with SIB
- Where
- 88 sites in Germany
- Volunteers
- 2,324 people
- Sponsor
- University Hospital Schleswig-Holstein
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Breast Cancer
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
This prospective, non-interventional time and motion study will evaluate the costs of healthcare resource utilization associated with the administration of trastuzumab (Herceptin) SC and IV formulations in HER2-positive EBC.
- Trial name
- NCT02658461
- Testing
- Trastuzumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Chemotherapy Effect
Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment
The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the…
- Conditions
- Breast Cancer, Chemotherapy Effect, Sentinel Lymph Node
- Trial name
- MagNeo (NCT05985551)
- Testing
- SLND or TAD by the magnetic technique (SPIO)
- Where
- Sweden
- Volunteers
- 114 people
- Sponsor
- Uppsala University
Breast Neoplasms, Survivorship
Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer
The purpose of this randomized controlled trial is to evaluate the effectiveness of an empirically supported psychosocial treatment, Acceptance and Commitment Therapy, in facilitating improved quality of life, benefit-finding…
- Conditions
- Breast Neoplasms, Survivorship, Stress
- Trial name
- ACT (NCT01164930)
- Testing
- Acceptance and Commitment Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- San Jose State University
ER-positive Her2-negative Early Breast Cancer
Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer
The need/benefit of adjuvant chemotherapy could be negligible for a certain category of patient with newly diagnosed unilateral non metastatic breast cancer.
- Trial name
- OPTIGEN (NCT03080428)
- Testing
- Genomic test
- Sponsor
- UNICANCER
Breast Cancer
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
This multicenter study in participants with HER2-positive eBC will investigate participants' pain and discomfort of SC trastuzumab (Herceptin) administered either via a single-use injection device (SID) or via vial for manual…
- Trial name
- ESCAPE (NCT02194166)
- Testing
- Trastuzumab, Paclitaxel, Docetaxel
- Where
- 7 sites in Belarus, Kazakhstan
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
TNBC - Triple-Negative Breast Cancer
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Triple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC…
- Trial name
- NCT06627712
- Testing
- SBRT+PD-1 Inhibitor + Chemotherapy, PD-1 Inhibitor + Chemotherapy
- Where
- China
- Volunteers
- 318 people
- Sponsor
- West China Hospital
Breast Cancer
Intraoperative Radiotherapy for Early Stage Breast Cancer
Up to 200 patients with biopsy proven early stage breast cancer selecting Wide Local Excision (WLE) will undergo mammography, ultrasound (of affected breast and ipsilateral axilla) and contrast enhanced-magnetic resonance imaging…
- Trial name
- IORT (NCT01189851)
- Testing
- Intraoperative Radiotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating tumour cells (CTC) in peripheral blood.
- Conditions
- Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells
- Trial name
- TREAT-CTC (NCT01548677)
- Testing
- trastuzumab
- Where
- 80 sites in Belgium, France and 2 more
- Volunteers
- 1,317 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Prehabilitation
Multimodal Prehabilitation Program That Combines Physical Exercise, Psychological Intervention and Nutritional Support to Improve the Response to Neoadjuvant Chemoterhapy in Early Breast Cancer Patients
The aim of this clinical trial is to evaluate whether following a multimodal prehabilitation program including physical exercise, nutritional support and psychological intervention during neoadjuvant chemotherapy in breast cancer…
- Trial name
- DIANA (NCT07107594)
- Testing
- Multimodal prehabilitation
- Where
- Spain
- Volunteers
- 214 people
- Sponsor
- Hospital Clinic of Barcelona
Breast Cancer, Infertility
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Goserelin may help prevent early menopause in patients undergoing chemotherapy for breast cancer. It is not yet known whether goserelin is effective in preventing early menopause in women undergoing chemotherapy for…
- Conditions
- Breast Cancer, Infertility, Menopausal Symptoms
- Trial name
- NCT00427245
- Testing
- cyclophosphamide, goserelin acetate, adjuvant therapy
- Where
- 66 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
Breast Cancer
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as CP-751871, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00635245
- Testing
- figitumumab, imaging biomarker analysis, laboratory biomarker analysis
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.